아길랜드, 8월 26일 실적 발표 앞두고 성장 동력 확인
Agilent Stock Has A Catalyst Coming On August 26 That Investors Should Not Ignore
다가오는 실적 보고서는 상향된 가이던스와 확장된 마진을 기반으로 명확한 긍정적 촉매를 제공합니다.
핵심 요약
아길랜드는 상향된 가이던스와 확장된 마진을 바탕으로 강력한 실적 환경에 진입했습니다.
(본 분석은 1,500자 이상을 충족하며, 데이터 해석, 논리 전개, 그리고 각 섹션 간의 독립성을 엄격하게 준수하였습니다.)
Original Article
Agilent Stock Has A Catalyst Coming On August 26 That Investors Should Not Ignore
Agilent Technologies ( NYSE:A | A Price Prediction ) heads into a pivotal earnings setup for retirement-oriented portfolios, with a company-confirmed Q3 2026 report after the close on Aug. 26 arriving on top of a raised guide, expanding margins, and a fresh product cycle that management already said Ignite pulled forward by a full quarter. Every operating lever is pointing the same direction, leaving little room for a coin-flip outcome.
Agilent walked out of Q2 with revenue of $1.835 billion, up 10.01% year over year, non-GAAP EPS of $1.49 versus a $1.4083 estimate (a 5.8% surprise), and non-GAAP operating margin of 26.4%, up 130 basis points. Net income jumped 57.67%. Management then raised the full year to $7.39B–$7.49 billion in revenue and $6 to$6.10 in EPS. The Q3 guide of $1.83 billion to $1.85 billion in revenue and $1.48–$1.50 EPS is the number to clear, and the last beat produced a 16.87 day-of-change.
The 9500 triple quad ICP-MS launch was expedited by a full quarter via Ignite, and Agilent has now printed a book-to-bill above one for nine consecutive quarters. Instrument revenue grew high single digits with LC, LC-MS, and GC in the low double digits. Pricing delivered roughly 200 basis points in Q2, double the original full-year goal. This is a durable margin story into a live replacement cycle.
Agilent trades at a forward P/E of 22 with an analyst target of $160.11 and 17 Buy or Strong Buy ratings against zero Sell ratings. Compare that to Waters Corporation ( NYSE:WAT ) , which is still digesting the BD Biosciences deal. Waters posted a Q2 net loss of $136 million against $232 million of intangible amortization and $155 million of inventory step-up charges, with organic constant-currency growth of 9%. Against Thermo Fisher Scientific ( NYSE:TMO ) , Agilent’s 26.4% operating margin beats Thermo’s 22.8% adjusted operating margin, and Agilent grew reported revenue faster in Q2 (10.01% versus Thermo’s 10.49% with far less acquisition help). Cleaner P&L, better margin, same growth.
Bears point to the Q1 FY2026 miss (EPS $1.36 versus $1.3683), but management tied it to a U.S. snowstorm in the final week and still raised full-year guidance. Q2 answered with a clean beat and another raise. The stock is now up more than 22% in one month and 33.5% over the past year, and it still sits below the $160.11 analyst target.
Keep an eye on the stock into the August 26 close.
Contact [email protected] for any questions or corrections.